|
1
|
American Cancer Society. Global Cancer
Facts & Figures. 2nd edition. American Cancer Society; Atlanta,
GA: 2011
|
|
2
|
Negrini M, Nicoloso MS and Calin GA:
MicroRNAs and cancer - new paradigms in molecular oncology. Curr
Opin Cell Biol. 21:470–479. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Graveel CR, Calderone HM, Westerhuis JJ,
Winn ME and Sempere LF: Critical analysis of the potential for
microRNA biomarkers in breast cancer management. Breast Cancer
(Dove Med Press). 7:59–79. 2015.
|
|
5
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferracin M, Querzoli P, Calin GA and
Negrini M: MicroRNAs: Toward the clinic for breast cancer patients.
Semin Oncol. 38:764–775. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Masood S: Development of a novel approach
for breast cancer prediction and early detection using minimally
invasive procedures and molecular analysis: How cytomorphology
became a breast cancer risk predictor. Breast J. 21:82–96. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brunoro GV, Carvalho PC, Ferreira AT,
Perales J, Valente RH, de Moura Gallo CV, Pagnoncelli D and
Neves-Ferreira AG: Proteomic profiling of nipple aspirate fluid
(NAF): Exploring the complementarity of different peptide
fractionation strategies. J Proteomics. 117:86–94. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nizzoli R, Bozzetti C, Crafa P, Naldi N,
Guazzi A, Di Blasio B, Camisa R and Cascinu S: Immunocytochemical
evaluation of HER-2/neu on fine-needle aspirates from primary
breast carcinomas. Diagn Cytopathol. 28:142–146. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hornberger J, Chen SC, Li Q, Kakad P and
Quay SC: Proliferative epithelial disease identified in nipple
aspirate fluid and risk of developing breast cancer: A systematic
review. Curr Med Res Opin. 31:253–262. 2015. View Article : Google Scholar
|
|
11
|
Tredwell GD, Miller JA, Chow HH, Thompson
PA and Keun HC: Metabolomic characterization of nipple aspirate
fluid by (1)H NMR spectroscopy and GC-MS. J Proteome Res.
13:883–889. 2014. View Article : Google Scholar
|
|
12
|
Chatterton RT, Muzzio M, Heinz R, Gann PH
and Khan SA: Methodological considerations in estrogen assays of
breast fluid and breast tissue. Steroids. 99:103–107. 2015.
View Article : Google Scholar
|
|
13
|
Dunmire V, Wu C, Symmans WF and Zhang W:
Increased yield of total RNA from fine-needle aspirates for use in
expression microarray analysis. Biotechniques. 33:890–896.
2002.PubMed/NCBI
|
|
14
|
Evron E, Dooley WC, Umbricht CB, Rosenthal
D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE,
et al: Detection of breast cancer cells in ductal lavage fluid by
methylation-specific PCR. Lancet. 357:1335–1336. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Assersohn L, Gangi L, Zhao Y, Dowsett M,
Simon R, Powles TJ and Liu ET: The feasibility of using fine needle
aspiration from primary breast cancers for cDNA microarray
analyses. Clin Cancer Res. 8:794–801. 2002.PubMed/NCBI
|
|
16
|
Phillips TA, Fabian CJ, Kimler BF and
Petroff BK: Assessment of RNA in human breast tissue sampled by
random periareolar fine needle aspiration and ductal lavage and
processed as fixed or frozen specimens. Reprod Biol. 13:75–81.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Danforth DN, Warner AC, Wangsa D, Ried T,
Duelli D, Filie AC and Prindiville SA: An improved breast
epithelial sampling method for molecular profiling and biomarker
analysis in women at risk for breast cancer. Breast Cancer (Auckl).
9:31–40. 2015.
|
|
18
|
Masood S: Cytomorphology as a risk
predictor: experience with fine needle aspiration biopsy, nipple
fluid aspiration, and ductal lavage. Clin Lab Med. 25:827–843.
viii–ix. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saeed AI, Sharov V, White J, Li J, Liang
W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, et
al: TM4: A free, open-source system for microarray data management
and analysis. Biotechniques. 34:374–378. 2003.PubMed/NCBI
|
|
20
|
Vlachos IS, Kostoulas N, Vergoulis T,
Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD,
Prionidis K, Dalamagas T and Hatzigeorgiou AG: DIANA miRPath v2.0:
Investigating the combinatorial effect of microRNAs in pathways.
Nucleic Acids Res. 40(W1): W498–W504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin L, Wessely O, Marcusson EG, Ivan C,
Calin GA and Alahari SK: Prooncogenic factors miR-23b and miR-27b
are regulated by Her2/Neu, EGF, and TNF-α in breast cancer. Cancer
Res. 73:2884–2896. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Becker LE, Takwi AA, Lu Z and Li Y: The
role of miR-200a in mammalian epithelial cell transformation.
Carcinogenesis. 36:2–12. 2015. View Article : Google Scholar :
|
|
23
|
Ebrahimi F, Gopalan V, Smith RA and Lam
AK: miR-126 in human cancers: Clinical roles and current
perspectives. Exp Mol Pathol. 96:98–107. 2014. View Article : Google Scholar
|
|
24
|
Shi Y, Qiu M, Wu Y and Hai L: MiR-548-3p
functions as an anti-oncogenic regulator in breast cancer. Biomed
Pharmacother. 75:111–116. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kang H, Kim C, Lee H, Rho JG, Seo JW, Nam
JW, Song WK, Nam SW, Kim W and Lee EK: Downregulation of
microRNA-362-3p and microRNA-329 promotes tumor progression in
human breast cancer. Cell Death Differ. 23:484–495. 2016.
View Article : Google Scholar
|
|
26
|
Ell B, Qiu Q, Wei Y, Mercatali L, Ibrahim
T, Amadori D and Kang Y: The microRNA-23b/27b/24 cluster promotes
breast cancer lung metastasis by targeting metastasis-suppressive
gene prosaposin. J Biol Chem. 289:21888–21895. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y,
Li C, Chong M, Ibrahim T, Mercatali L, et al: miR-126 and miR-126*
repress recruitment of mesenchymal stem cells and inflammatory
monocytes to inhibit breast cancer metastasis. Nat Cell Biol.
15:284–294. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Taylor MA, Sossey-Alaoui K, Thompson CL,
Danielpour D and Schiemann WP: TGF-β upregulates miR-181a
expression to promote breast cancer metastasis. J Clin Invest.
123:150–163. 2013. View
Article : Google Scholar :
|
|
29
|
Tuomarila M, Luostari K, Soini Y, Kataja
V, Kosma VM and Mannermaa A: Overexpression of microRNA-200c
predicts poor outcome in patients with PR-negative breast cancer.
PLoS One. 9:e1095082014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Y, Cai Q, Bao PP, Su Y, Cai H, Wu J,
Ye F, Guo X, Zheng W, Zheng Y, et al: Tumor tissue microRNA
expression in association with triple-negative breast cancer
outcomes. Breast Cancer Res Treat. 152:183–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hoppe R, Achinger-Kawecka J, Winter S,
Fritz P, Lo WY, Schroth W and Brauch H: Increased expression of
miR-126 and miR-10a predict prolonged relapse-free time of primary
oestrogen receptor-positive breast cancer following tamoxifen
treatment. Eur J Cancer. 49:3598–3608. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang R, Li Y, Dong X, Peng L and Nie X:
MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1
in breast cancer. Med Oncol. 31:3472014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tan X, Peng J, Fu Y, An S, Rezaei K,
Tabbara S, Teal CB, Man YG, Brem RF and Fu SW: miR-638 mediated
regulation of BRCA1 affects DNA repair and sensitivity to UV and
cisplatin in triple-negative breast cancer. Breast Cancer Res.
16:4352014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu H, Li S, Cui X, Lv X, Jiao Y, Yu F, Yao
H, Song E, Chen Y, Wang M, et al: The overexpression of
hypomethylated miR-663 induces chemotherapy resistance in human
breast cancer cells by targeting heparin sulfate proteoglycan 2
(HSPG2). J Biol Chem. 288:10973–10985. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu Q, Wang C, Lu Z, Guo L and Ge Q:
Analysis of serum genome-wide microRNAs for breast cancer
detection. Clin Chim Acta. 413:1058–1065. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guo LJ and Zhang QY: Decreased serum
miR-181a is a potential new tool for breast cancer screening. Int J
Mol Med. 30:680–686. 2012.PubMed/NCBI
|
|
37
|
Chan M, Liaw CS, Ji SM, Tan HH, Wong CY,
Thike AA, Tan PH, Ho GH and Lee AS: Identification of circulating
microRNA signatures for breast cancer detection. Clin Cancer Res.
19:4477–4487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Godfrey AC, Xu Z, Weinberg CR, Getts RC,
Wade PA, DeRoo LA, Sandler DP and Taylor JA: Serum microRNA
expression as an early marker for breast cancer risk in
prospectively collected samples from the Sister Study cohort.
Breast Cancer Res. 15:R422013. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H
and Hu C: Circulating microRNA-92a and microRNA-21 as novel
minimally invasive biomarkers for primary breast cancer. J Cancer
Res Clin Oncol. 139:223–229. 2013. View Article : Google Scholar :
|
|
40
|
Kodahl AR, Zeuthen P, Binder H, Knoop AS
and Ditzel HJ: Alterations in circulating miRNA levels following
early-stage estrogen receptor-positive breast cancer resection in
post-menopausal women. PLoS One. 9:e1019502014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Madhavan D, Zucknick M, Wallwiener M, Cuk
K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R,
et al: Circulating miRNAs as surrogate markers for circulating
tumor cells and prognostic markers in metastatic breast cancer.
Clin Cancer Res. 18:5972–5982. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Na RS, EGX, Sun W, Sun XW, Qiu XY, Chen LP
and Huang YF: Expressional analysis of immune-related miRNAs in
breast milk. Genet Mol Res. 14:11371–11376. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ma F, Zhang J, Zhong L, Wang L, Liu Y,
Wang Y, Peng L and Guo B: Upregulated microRNA-301a in breast
cancer promotes tumor metastasis by targeting PTEN and activating
Wnt/β-catenin signaling. Gene. 535:191–197. 2014. View Article : Google Scholar
|
|
44
|
Keklikoglou I, Koerner C, Schmidt C, Zhang
JD, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T,
Schneeweiss A, et al: MicroRNA-520/373 family functions as a tumor
suppressor in estrogen receptor negative breast cancer by targeting
NF-κB and TGF-β signaling pathways. Oncogene. 31:4150–4163. 2012.
View Article : Google Scholar
|
|
45
|
Wang X, Li Y, Qi W, Zhang N, Sun M, Huo Q,
Cai C, Lv S and Yang Q: MicroRNA-99a inhibits tumor aggressive
phenotypes through regulating HOXA1 in breast cancer cells.
Oncotarget. 6:32737–32747. 2015.PubMed/NCBI
|
|
46
|
Volinia S and Croce CM: Prognostic
microRNA/mRNA signature from the integrated analysis of patients
with invasive breast cancer. Proc Natl Acad Sci USA. 110:7413–7417.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yu H, Li H, Qian H, Jiao X, Zhu X, Jiang
X, Dai G and Huang J: Upregulation of miR-301a correlates with poor
prognosis in triple-negative breast cancer. Med Oncol. 31:2832014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ye FG, Song CG, Cao ZG, Xia C, Chen DN,
Chen L, Li S, Qiao F, Ling H, Yao L, et al: Cytidine deaminase axis
modulated by miR-484 differentially regulates cell proliferation
and chemoresistance in breast cancer. Cancer Res. 75:1504–1515.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wu J, Li S, Jia W, Deng H, Chen K, Zhu L,
Yu F and Su F: Reduced let-7a is associated with chemoresistance in
primary breast cancer. PLoS One. 10:e01336432015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lv J, Xia K, Xu P, Sun E, Ma J, Gao S,
Zhou Q, Zhang M, Wang F, Chen F, et al: miRNA expression patterns
in chemoresistant breast cancer tissues. Biomed Pharmacother.
68:935–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yu L, Yang Y, Hou J, Zhai C, Song Y, Zhang
Z, Qiu L and Jia X: MicroRNA-144 affects radiotherapy sensitivity
by promoting proliferation, migration and invasion of breast cancer
cells. Oncol Rep. 34:1845–1852. 2015.PubMed/NCBI
|
|
52
|
Zearo S, Kim E, Zhu Y, Zhao JT, Sidhu SB,
Robinson BG and Soon PS: MicroRNA-484 is more highly expressed in
serum of early breast cancer patients compared to healthy
volunteers. BMC Cancer. 14:2002014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hatse S, Brouwers B, Dalmasso B, Laenen A,
Kenis C, Schöffski P and Wildiers H: Circulating microRNAs as
easyto-measure aging biomarkers in older breast cancer patients:
Correlation with chronological age but not with fitness/frailty
status. PLoS One. 9:e1106442014. View Article : Google Scholar
|
|
54
|
McDermott AM, Miller N, Wall D, Martyn LM,
Ball G, Sweeney KJ and Kerin MJ: Identification and validation of
oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS
One. 9:e870322014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chang CW, Wu HC, Terry MB and Santella RM:
microRNA expression in prospectively collected blood as a potential
biomarker of breast cancer risk in the BCFR. Anticancer Res.
35:3969–3977. 2015.PubMed/NCBI
|
|
56
|
Gu YQ, Gong G, Xu ZL, Wang LY, Fang ML,
Zhou H, Xing H, Wang KR and Sun L: miRNA profiling reveals a
potential role of milk stasis in breast carcinogenesis. Int J Mol
Med. 33:1243–1249. 2014.PubMed/NCBI
|
|
57
|
Xi Y, Jiang X, Li R, Chen M, Song W and Li
X: The levels of human milk microRNAs and their association with
maternal weight characteristics. Eur J Clin Nutr. Oct 21–2015.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
